65,437 trials
Post-endoscopic Mucosal Resection of Colon Polyps
Primary: Positive Recurrent Adenomas Using White Light Imaging — 66 adenomas with positive diagnoses
Atrophic Vaginitis · Menopause
Primary: Vaginal Dryness — -5.48; -5.76 units on a scale
Glaucoma and Ocular Hypertension
Primary: Summary of Change From Baseline Average Intraocular Pressure Diurnal Measurement by Treatment Group Population (Cohort 1) — -5.10; -6.65; -3.17; -5.67 mm Hg — p=<0.001
HIV/AIDS
Primary: Number Interested in Participating — 2; 34; 90 Participants
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude
Disorder Related to Lung Transplantation · Central Airway Stenosis · Airway Exudative Plaques
Primary: Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy. — 4; 4 Participants — p=1
Leukemia, Acute Myeloid (AML)
Primary: Duration of Overall Survival (OS) — 9.3; 5.6 Months — p=0.0004
Tonsillectomy
Primary: Difference in Number of Days Requiring Rescue Pain Medication — 5.00; 5.75 Days
Coronary Heart Disease
Primary: Count of Participants With MACE (Major Acute Cardiovascular Events) — 0 Participants
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.3; 10.2 percentage points — p=< 0.0001
Periodontitis
Primary: Change in Clinical Attachment Levels (CAL) — -2.2; -2.1 mm
Cholecystitis
Primary: Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis — 9; 0; 1; 1 Participants
Chronic Sinusitis · Nasal Polyposis
Primary: Change in Lund-Kennedy Endoscopic Scores — -8.0; -1.5; -6.9 score on a scale
Sleep Initiation and Maintenance Disorders · Alzheimer Disease
Primary: Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4 — 73.4; 45.2 Minutes — p=0.00128
Melanoma
Primary: Number of Participants With T-cell Response to Peptide Vaccine — 6; 1; 12; 19 Participants